Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis
Version of Record online: 11 SEP 2012
© 2012 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 36, Issue 9, pages 866–874, November 2012
How to Cite
Bajaj, J. S., Ratliff, S. M., Heuman, D. M. and Lapane, K. L. (2012), Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Alimentary Pharmacology & Therapeutics, 36: 866–874. doi: 10.1111/apt.12045
- Issue online: 3 OCT 2012
- Version of Record online: 11 SEP 2012
- Manuscript Accepted: 22 AUG 2012
- Manuscript Revised: 7 AUG 2012
- Manuscript Revised: 6 AUG 2012
- Manuscript Received: 27 JUL 2012
- McGuire Research Institute. Grant Number: RO1DK087913
- NIDDK. Grant Number: RO1AA020203
There is increasing evidence that proton pump inhibitors (PPIs) increase the rate of infections in patients with decompensated cirrhosis.
To estimate the extent to which proton pump inhibitors (PPIs) increase the rate of infections among patients with decompensated cirrhosis.
We conducted a retrospective propensity-matched new user design using US Veterans Health Administration data. Only decompensated cirrhotic patients from 2001 to 2009 were included. New PPI users after decompensation (n = 1268) were 1:1 matched to those who did not initiate gastric acid suppression. Serious infections, defined as infections associated with a hospitalisation, were the outcomes. These were separated into acid suppression-related (SBP, bacteremia, Clostridium difficile and pneumonia) and non-acid suppression-related. Time-varying Cox models were used to estimate adjusted hazard ratios (HR) and 95% CIs of serious infections. Parallel analyses were conducted with H2 receptor antagonists (H2RA).
More than half of persons with decompensated cirrhosis were new users of gastric acid suppressants, with most using PPIs (45.6%) compared with H2RAs (5.9%). In the PPI propensity-matched analysis, 25.3% developed serious infections and 25.9% developed serious infections in the H2RA analysis. PPI users developed serious infections faster than nongastric acid suppression users (adjusted HR: 1.66; 95% CI: 1.31–2.12). For acid suppression-related serious infections, PPI users developed the outcome at a rate 1.75 times faster than non-users (95% CI: 1.32–2.34). The H2RA findings were not statistically significant (HR serious infections: 1.59; 95% CI: 0.80–3.18; HR acid suppression-related infections: 0.92; 95% CI: 0.31–2.73).
Among patients with decompensated cirrhosis, proton pump inhibitors but not H2 receptor antagonists increase the rate of serious infections.